Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss

siteadmin January 17, 2022

MONTPELLIER, France–()–Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders,…

Source: www.businesswire.comRead more